Ideal Candidates for Nivolumab Clinical Trials: What You Need to Know
Discover the key eligibility criteria for participating in Nivolumab clinical trials. This article covers age, health status, and specific medical conditions to help potential candidates understand if they qualify for this promising cancer immunotherapy study. Learn what health benchmarks are necessary and why proper candidate selection is crucial for successful trial outcomes.
Ideal Candidates for Nivolumab Clinical Trials: What You Need to Know
Nivolumab is a human-derived monoclonal antibody used in immunotherapy for various cancers. Sponsored by the U.S. National Institutes of Health, these clinical trials aim to evaluate its effectiveness in cancer treatment. Each study targets specific patient groups, meaning eligibility can vary. Generally, suitable candidates meet certain criteria, such as age, cancer diagnosis, and health status, to ensure safety and reliable results.
- Participants should be adults aged 18 or older, capable of consenting independently; parental consent is needed for minors.
- They must have confirmed diagnosis of the targeted cancer type, including relapsed or previously treated cases, or be classified as high risk per the International Prognostic Scoring System (IPSS).
- Participants should willingly sign an IRB-approved informed consent form.
- Individuals with a history of immune checkpoint inhibitor therapy are generally ineligible.
- They should not have concurrent malignancies.
- Adherence to ECOG performance status requirements is necessary for trial participation.
- Female candidates must not be pregnant and should commit to contraception during the trial.
- Other organ functions must be within acceptable ranges, with specific levels for blood components and serum creatinine.
- Recent chemotherapy (within four weeks) may disqualify applicants.
